Barclays (LON:BARC) analyst Peter Lawson maintained a Buy rating on Immunomedics (NASDAQ:IMMU) on Monday, setting a price target of $48, which is approximately 27.86% above the present share price of $37.54.
Lawson expects Immunomedics to post earnings per share (EPS) of -$0.44 for the third quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Immunomedics, with an average price target of $44.38.
The analysts price targets range from a high of $56 to a low of $31.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$81.97 million. The company's market cap is $9.38 billion.
According to TipRanks.com, Barclays analyst Peter Lawson is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.4% and a 47.22% success rate.
Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.